Weiss Multi Strategy Advisers LLC Has $133,000 Stake in Catalyst Pharmaceuticals, Inc. (CPRX)

Weiss Multi Strategy Advisers LLC maintained its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 68,000 shares of the biopharmaceutical company’s stock at the end of the first quarter. Weiss Multi Strategy Advisers LLC owned 0.08% of Catalyst Pharmaceuticals worth $133,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the company. Candriam Luxembourg S.C.A. purchased a new stake in shares of Catalyst Pharmaceuticals during the first quarter valued at approximately $1,170,000. Berson & Corrado Investment Advisors LLC raised its stake in Catalyst Pharmaceuticals by 31.7% in the first quarter. Berson & Corrado Investment Advisors LLC now owns 251,025 shares of the biopharmaceutical company’s stock worth $489,000 after buying an additional 60,425 shares during the period. Knott David M bought a new stake in Catalyst Pharmaceuticals during the first quarter worth about $554,000. Oxford Asset Management raised its stake in Catalyst Pharmaceuticals by 138.1% in the first quarter. Oxford Asset Management now owns 58,940 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 34,181 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in Catalyst Pharmaceuticals during the first quarter worth about $746,000. Institutional investors own 30.09% of the company’s stock.

Catalyst Pharmaceuticals, Inc. (NASDAQ CPRX) opened at 2.83 on Tuesday. The stock’s market cap is $237.11 million. Catalyst Pharmaceuticals, Inc. has a one year low of $0.68 and a one year high of $3.16. The company has a 50-day moving average price of $2.33 and a 200-day moving average price of $1.62.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.06) EPS for the quarter, hitting analysts’ consensus estimates of ($0.06). On average, analysts anticipate that Catalyst Pharmaceuticals, Inc. will post ($0.26) earnings per share for the current year.

WARNING: “Weiss Multi Strategy Advisers LLC Has $133,000 Stake in Catalyst Pharmaceuticals, Inc. (CPRX)” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://sportsperspectives.com/2017/07/18/weiss-multi-strategy-advisers-llc-has-133000-stake-in-catalyst-pharmaceuticals-inc-cprx-updated-updated.html.

CPRX has been the subject of a number of recent research reports. Zacks Investment Research upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research note on Monday, May 22nd. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Catalyst Pharmaceuticals in a research note on Monday, March 20th. Finally, Roth Capital set a $3.00 price target on Catalyst Pharmaceuticals and gave the company a “buy” rating in a report on Monday, March 20th.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply